Compare Fox Corp Class A (FOXA) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Tango Therapeutics Inc. — how do they compare? Fox Corp Class A trades at $62.63 (market cap $24.93B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Fox Corp Class A is far larger — about 6.6× Tango Therapeutics Inc.'s market cap, and Fox Corp Class A pays a 0.93% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 35 Days and Tango Therapeutics Inc. for 0 Days on average.
| FOXA | TNGX | |
|---|---|---|
Market Cap | $24.93B | $3.75B |
Volume | 2,221,953 | 9,619,106 |
Sector | Media | Health |
52-Week High | $76.11 | $32.90 |
52-Week Low | $48.79 | $7.50 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $28.30B | $2.77B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fox Corporation (FOXA) trades at $62.50, down slightly by 0.14% with a bearish technical signal. The company shows strong fundamentals with revenue growth from $14.0B in 2024 to $16.3B in 2025 and consistent earnings beats. Analyst consensus is bullish with a $72.00 price target, though the pending $22B Roku acquisition faces DOJ scrutiny. Cash flow improved significantly to $1.03B net in 2025, while 2026 projections show potential pressure.
FOXA presents a compelling value opportunity with reasonable valuations (P/E 16.3) and strong profitability (ROE 14.29%). The Roku deal represents both growth potential and regulatory risk. With zero sell ratings and insider buying, institutional sentiment remains positive despite technical weakness. Key risks include integration challenges and advertising market volatility.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
